African Min. (AMI) 뉴스

You should try to remember, as we discuss the ADL co-primary, that (1) the EMA is not requiring it and (2) the FDA is planning to drop it. So, at the heart of this discussion, it's not true that " he issue is with the [ADL] endpoint outcome." The remaining issue, to the extent one exists, is the tim

frrol
My thinking is that the EMA accepted the filing and the peer review group also, but I do agree that just meeting an endpoint is not enough, The data needs to be convincing.

So, I guess you feel that the peer review group are knuckleheads? Also, that the EMA are knucklehe

Good morning all. 




TPTW........!!!!!!

Good morning all.  

All good of course, if they pull it off.  The thing is they need money to purchase the minority acquisition.   But like I said, if they do pull it off, that will propel this much much higher imo.  

Gotta get out of EM and somehow state they have rejiggered financing for debts, acquisi

$$$ Today is the Day $$$$

$$$$ $FRX $$$$

Next Tuesday! 7:00pm(US EST) for the next .... dog and pony show? Will the market shrug at $mONI again? Or will the internet savior, Mr October, save the day with his massive knowledge of internet search engines? He can buy a hotrod, he can sell a Honda, he is passionate about diversity and can coa

💹 $9.99 💹HIGH Sell Orders💹 Good Advice 💹💹💹

The public comments supporting the current FDA draft awaiting finalization included JNJ and I believe other BPs. So I don't see how your theory makes any sense. No commenter opposed the basic change of dropping the ADL co-primary endpoint for early AD. (Apparently, Doc328 didn't comment.)

It's going to be quiet day here.....https://www.npr.org/2025/01/09/nx-s1-5251459/u-s-stock-markets-close-mourning-former-president-jimmy-carter

George, good information. Thank you. The TGA historically follows the FDA and has considered the FDA to be the gold standard. However, this information gives the TGA a clear path to not wait for FDA approval if the EMA approves 2-73 first. Just another bullet in the chamber for quicker revenue g

Formerly #09072Q106 - FKA bioaq
For those who enjoy statements supported by court documents:
Yes, I understand you "think" you're smart. ♿️
Chapter 11 providing creditor protection was temporary. You can call it whatever you like.

JRoon, yes I agree. But if they knowlingly allow GIPE for CVD, it would come down to actually proving an intent to infringe. What is in the formulary for CVD?

I see my question is answered in posts between you and sleven.
Thx

A little bit about Wolfpack, Feuerstein and Larry Smith.

Since it seems memory lane to Adam Feuersteins decade long vendetta of manipulation of NWBO has opened this week, I came across one of his many hitpieces

"Blame for Northwest Bio Collapse Lies With CEO, Not With M

Lots of💹HISTORIC $HIRU XPERT interest wow💹https://ih.advfn.com/stock-market/USOTC/hiru-pk-HIRU/historical

The current price drop from 14 to 11.15 and close 11.43

1) Trend is still up with support @ 10+ rejected 6 times before crossing!
2) 10.50 successfully back tested the spike high at 14.44
3) Pattern remains bullish with a very large base suggesting higher prices
4

Morning Kool aide. The new lemon lime flavor seems to be a hit. There's no buyout, stop the rumors. This has seen its peak, and with whatever kool aide flavors your drinking orange, fruit punch, or the new lemon lime, its run its course and not going to see those levels again. Also, Pay Mikah. The

If that were true, there would never even have been a draft guidance at all.

Hey buddy, no he didn’t. I will reach out soon. I have faith he hasn’t abandoned us. I do think 2025 has to be the make or break year. We’re current, there was no massive sell offs at end of year. Just wish GEGP had someone who could communicate with the shareholders. I mean we went to 0041 in Sept

ALEANNA RESOURCES, LLC | ALEANNA ITALIA SPA © 2008-2024

https://www.aleannaitalia.com/en/home/

Indeed, I’m still eagerly and excitedly waiting for your first meaningful post on this forum, with some thorough analysis or reporting.